Bioventus Inc. 8-K Summary: 2025 Annual Meeting Results
Business Context and Reporting Period
This Form 8-K reports the results of Bioventus Inc.'s 2025 Annual Meeting of Stockholders held on June 3, 2025. The filing details the election of Class I directors and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
A total of 73,619,248 shares were present or represented by proxy, representing approximately 89.76% of outstanding shares entitled to vote. The following Class I directors were elected to serve until the 2026 annual meeting:
- Robert E. Claypoole: 64,865,453 For; 162,134 Withheld
- Philip G. Cowdy: 64,640,309 For; 387,278 Withheld
- Michelle McMurry-Heath: 64,834,950 For; 192,637 Withheld
- Guido J. Neels: 64,838,865 For; 188,722 Withheld
- Guy P. Nohra: 64,621,912 For; 405,675 Withheld
- Martin P. Sutter: 58,086,800 For; 6,940,787 Withheld
Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 73,459,057 votes For and 149,101 votes Against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding as of the April 7, 2025 record date to confirm the 89.76% participation rate.
- Note the significantly higher "Withheld" votes for director Martin P. Sutter (6,940,787) compared to other nominees.
- Confirm the tenure of the newly elected Class I directors extends through the 2026 annual meeting.
- Verify the appointment of Grant Thornton LLP for the fiscal year ending December 31, 2025.